Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2005 1
2006 2
2007 1
2008 3
2009 3
2010 3
2011 4
2012 1
2013 3
2014 1
2015 3
2016 2
2018 4
2019 3
2020 5
2021 4
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
VEGFC Antibody Therapy Drives Differentiation of AML.
Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Mulder AB, Guryev V, Verhagen HJMP, De Keersmaecker K, Smit L, Kornblau SM, De Bont ESJM. Kampen KR, et al. Among authors: ter elst a. Cancer Res. 2018 Oct 15;78(20):5940-5948. doi: 10.1158/0008-5472.CAN-18-0250. Epub 2018 Sep 5. Cancer Res. 2018. PMID: 30185550
Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.
Kramer C, Lanjouw L, Ruano D, Ter Elst A, Santandrea G, Solleveld-Westerink N, Werner N, van der Hout AH, de Kroon CD, van Wezel T, Berger L, Jalving M, Wesseling J, Smit V, de Bock GH, van Asperen CJ, Mourits M, Vreeswijk M, Bart J, Bosse T. Kramer C, et al. Among authors: ter elst a. J Pathol. 2024 Feb;262(2):137-146. doi: 10.1002/path.6218. Epub 2023 Oct 18. J Pathol. 2024. PMID: 37850614
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Zwierenga F, van Veggel B, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering Kappelle LBM, Ter Elst A, Hashemi SMS, Dingemans AC, van der Leest C, de Langen AJ, van den Heuvel MM, van der Wekken AJ. Zwierenga F, et al. Among authors: ter elst a. Lung Cancer. 2022 Aug;170:133-140. doi: 10.1016/j.lungcan.2022.06.012. Epub 2022 Jun 23. Lung Cancer. 2022. PMID: 35777160 Free article. Clinical Trial.
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.
Koopman B, Groen HJM, Schuuring E, Hiltermann TJN, Timens W, den Dunnen WFA, van den Berg A, Ter Elst A, van Kruchten M, Kluiver JL, Hiddinga BI, Hijmering-Kappelle LBM, Groves MR, Vilacha JF, van Kempen LC, van der Wekken AJ. Koopman B, et al. Among authors: ter elst a. Clin Lung Cancer. 2022 Mar;23(2):e104-e115. doi: 10.1016/j.cllc.2021.06.011. Epub 2021 Jul 3. Clin Lung Cancer. 2022. PMID: 34325996 Free article. Review.
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B, Groen HJM, Ligtenberg MJL, Grünberg K, Monkhorst K, de Langen AJ, Boelens MC, Paats MS, von der Thüsen JH, Dinjens WNM, Solleveld N, van Wezel T, Gelderblom H, Hendriks LE, Speel EM, Theunissen TE, Kroeze LI, Mehra N, Piet B, van der Wekken AJ, Ter Elst A, Timens W, Willems SM, Meijers RWJ, de Leng WWJ, van Lindert ASR, Radonic T, Hashemi SMS, Heideman DAM, Schuuring E, van Kempen LC. Koopman B, et al. Among authors: ter elst a. Oncologist. 2021 Aug;26(8):e1347-e1358. doi: 10.1002/onco.13580. Epub 2020 Nov 10. Oncologist. 2021. PMID: 33111480 Free PMC article.
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
van der Leest P, Hiddinga B, Miedema A, Aguirre Azpurua ML, Rifaela N, Ter Elst A, Timens W, Groen HJM, van Kempen LC, Hiltermann TJN, Schuuring E. van der Leest P, et al. Among authors: ter elst a. Mol Oncol. 2021 Nov;15(11):2910-2922. doi: 10.1002/1878-0261.13090. Epub 2021 Sep 25. Mol Oncol. 2021. PMID: 34449963 Free PMC article.
Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.
van Opijnen MP, Broekman MLD, Cuppen E, Dubbink HJ, Ter Elst A, van Eijk R, Mühlebner A, Jansen C, van der Geize R, Speel EM, Groenen PJTA, de Vos FYF, Wesseling P, de Leng WWJ, Maas SLN. van Opijnen MP, et al. Among authors: ter elst a. J Neurooncol. 2024 Feb;166(3):485-492. doi: 10.1007/s11060-024-04568-8. Epub 2024 Jan 29. J Neurooncol. 2024. PMID: 38285243 Free PMC article. Review.
45 results